Y-Intercept (HK)’s Oric Pharmaceuticals ORIC Stock Holding History

Y-Intercept (HK)’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-111,992	Closed	-$1.42M	–	2047
2026 Q1	$1.42M	Sell	111,992 -229,431	-67%	-$2.6M	0.03%	890
2025 Q4	$2.79M	Buy	+341,423	New	+$3.93M	0.06%	459
2022 Q3	–	Sell	-10,828	Closed	-$49K	–	1194
2022 Q2	$49K	Buy	+10,828	New	+$43.2K	0.01%	753

Other funds holding ORIC

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Y-Intercept (HK)'s ORIC Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 111,992 shares — an estimated $1.42M sold.

Y-Intercept (HK) first reported a position in ORIC in Q2 2022 and held it in 3 quarters. The position peaked at $2.79M in Q4 2025. 5 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Y-Intercept (HK) reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 111,992 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.42M.
Y-Intercept (HK) first reported a position in Oric Pharmaceuticals in Q2 2022 and held it in 3 quarters.
Y-Intercept (HK)'s Oric Pharmaceuticals position peaked at $2.79M in Q4 2025.
5 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.